Australia’s healthcare regulator TGA has enabled LTR Pharma (ASX:LTP) to dose the first patient with viagra nasal spray product SPONTAN. Patients were prescribed through one select clinic managing a special access scheme on behalf of the TGA. “The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma,” company chair Lee Rodne said. “It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment.” Rodne also noted the move allows the company to oversee real-world use of…